Who is Eligible to File a Lawsuit for Meningiomas After Using Depo-Provera

The Growing Legal Battle Over Depo-Provera and Meningiomas

The legal battle surrounding Depo-Provera lawsuits has accelerated dramatically as mounting evidence links the contraceptive to serious brain injuries. Women across the United States-and globally-are coming forward with claims that their use of Depo-Provera led to the development of meningiomas, a type of non-cancerous but potentially debilitating brain tumor. Lawsuits accuse Pfizer, the manufacturer, of failing to provide sufficient warnings and information about these risks.

At the heart of this litigation is the allegation that Pfizer knew or should have known for decades about the potential danger posed by medroxyprogesterone acetate, the active ingredient in Depo-Provera. Internal research dating back to the 1980s indicated a possible connection between progesterone and abnormal meningeal cell growth, yet the company continued to market the drug without sufficient warnings in the United States. Today, the cases have been consolidated into Multidistrict Litigation (MDL 3140) in the Northern District of Florida, bringing national attention to this growing mass tort litigation.

Globally, regulatory agencies in Canada, Europe, and Australia have already mandated stronger warnings or contraindications for Depo-Provera after studies demonstrated elevated risks of meningioma development. Meanwhile, U.S. regulatory agencies have been slower to act, leaving many American patients unaware of the potential dangers until it was too late. The lawsuits argue that this regulatory lag has resulted in thousands of avoidable injuries and legal claims.

The Scientific Evidence Linking Depo-Provera to Brain Tumors

At the center of the Depo-Provera brain tumor risk controversy is extensive scientific research indicating a strong association between long-term use of Depo-Provera and the development of meningiomas. A major 2024 study published in the British Medical Journal analyzed more than 108,000 women in France, identifying a 5.6-fold increase in the risk of developing intracranial meningiomas among those who used Depo-Provera for more than one year. The longer a woman used the drug, the greater her risk of developing these tumors.

Meningiomas develop in the meninges-the protective layers surrounding the brain and spinal cord. Although typically classified as benign, these tumors can cause devastating neurological symptoms depending on their size and location. Women who develop these tumors may experience chronic headaches, seizures, vision loss, cognitive impairment, and personality changes. In some cases, surgery is required to remove the tumor, but certain locations make surgery either highly risky or impossible.

The scientific link between progesterone and meningioma growth has been recognized for decades. Research as early as the 1980s discovered that meningiomas often contain high concentrations of progesterone receptors, suggesting that the hormone can stimulate tumor growth. Depo-Provera, which delivers high doses of synthetic progesterone, may contribute to this process through repeated exposure over months or years, significantly raising the risk for certain patients.

Early Research Pfizer Allegedly Ignored

One of the most damaging allegations in these lawsuits is that Pfizer failed to act on decades of research connecting progesterone to meningioma development. As early as 1983, studies had shown that meningiomas contained large numbers of progesterone receptors. Further studies throughout the 1980s and 1990s indicated that progesterone exposure could fuel tumor growth, while anti-progesterone drugs appeared to slow their progression. Despite this growing body of research, Depo-Provera was approved by the FDA in 1992 without any warning label addressing brain tumor risks.

Internal company documents uncovered in some lawsuits suggest Pfizer may have been aware of these risks for years but chose not to pursue stronger label warnings in the United States. Plaintiffs argue that while international regulators in Canada, Europe, and Australia required meningioma warnings, Pfizer kept U.S. patients and doctors in the dark, depriving them of crucial information needed for informed decision-making.

This alleged failure to warn is central to the litigation. Plaintiffs contend that if proper warnings had been issued earlier, many women could have opted for alternative contraceptives, reducing or eliminating their risk of developing brain tumors altogether. The lawsuits maintain that Pfizer placed profits above patient safety by not updating its labeling despite growing evidence of harm.

Who May Be Eligible to File a Lawsuit

Not every individual who used Depo-Provera will automatically qualify to join the litigation. Lawsuits focus on those who meet specific medical and legal criteria that establish a likely connection between Depo-Provera usage and the development of a meningioma. Understanding who qualifies is critical for anyone considering legal action.

Generally, plaintiffs eligible to file a meningioma lawsuits eligibility claim must have received multiple Depo-Provera injections over a prolonged period, typically a year or more. Since the risk appears to be dose-dependent, longer usage periods strengthen the potential claim. Additionally, plaintiffs must have received a medical diagnosis of meningioma-either through brain imaging studies or surgical pathology.

Age also plays a role in eligibility. Most lawsuits prioritize claims from women who were diagnosed under the age of 70, as it becomes more difficult to separate Depo-Provera as the cause of the tumor in older patients who face natural age-related risks of tumor development. Lastly, the timing of diagnosis matters-most plaintiffs must show that their diagnosis occurred at least several years after first receiving Depo-Provera to demonstrate the prolonged exposure that contributed to tumor growth.

Key Medical and Usage Criteria for Eligibility

For individuals evaluating whether they qualify for a Depo-Provera legal action, three primary medical and usage factors typically guide eligibility:

• Usage History: Most successful claims involve women who received at least two injections of Depo-Provera, typically administered every three months. The more injections received over time, the higher the cumulative dose of medroxyprogesterone acetate absorbed by the body.
• Diagnosis Timeline: Plaintiffs are generally diagnosed with meningioma at least three years after first beginning Depo-Provera injections. This timeline allows for the slow-growing nature of these tumors and helps demonstrate the causative link between drug exposure and tumor formation.
• Age at Diagnosis: Younger plaintiffs (typically under 70 years old) have stronger claims because their tumors are less likely to be attributed to natural aging processes alone.

These eligibility criteria reflect both the science behind the lawsuits and the practical challenges of proving causation in pharmaceutical litigation. Plaintiffs who meet these conditions are in a stronger position to file claims and potentially secure compensation for their injuries.

How Meningioma Symptoms May Affect Eligibility

The severity and type of symptoms associated with meningiomas also play a major role in determining the strength of a claim. Meningiomas can vary greatly in size, growth rate, and location, which directly influences how much they impact a person’s health and quality of life. Plaintiffs who experienced serious neurological symptoms are often in stronger legal positions.

Common symptoms include debilitating headaches, seizures, blurred or double vision, memory loss, personality changes, and in some cases, psychiatric disturbances such as anxiety or depression. Some individuals have required brain surgery or radiation therapy to treat their tumors, while others live with inoperable growths that must be regularly monitored with costly imaging studies.

Severe cases where meningiomas are inoperable or located near critical brain structures typically involve more complex treatment plans, higher medical costs, and permanent disability risks. These factors often strengthen both the legal argument and the potential financial recovery. Lawsuits also factor in lost wages, diminished earning capacity, emotional distress, and reduced quality of life as additional forms of compensable damages.

Legal Theories Being Asserted in Current Lawsuits

The lawsuits against Pfizer are grounded in several legal claims that address the company’s alleged failure to protect consumers. At the center of these cases is the charge of Pfizer failure to warn. Plaintiffs argue that Pfizer knew of the association between Depo-Provera and meningioma development for decades but failed to update U.S. warning labels, even as international regulators required such changes.

Failure to warn claims assert that Pfizer deprived patients and physicians of crucial safety information, preventing them from making fully informed decisions about using Depo-Provera. Plaintiffs maintain that had adequate warnings been provided, many women would have selected alternative contraceptive options, avoiding the increased risk of brain tumors entirely.

Another major legal argument involves defective design. Plaintiffs allege that Depo-Provera’s formulation, delivering high doses of synthetic progesterone, posed an unreasonably dangerous risk compared to safer, lower-dose alternatives that could have achieved similar contraceptive results. The lawsuits also assert negligence, product liability, and misrepresentation, alleging that Pfizer prioritized profits over patient safety while concealing or minimizing evidence of harm.

Current Status of Depo-Provera Litigation and MDL 3140

As of 2025, the Depo-Provera litigation has grown into a significant mass tort consolidated under Depo-Provera MDL 3140 in the Northern District of Florida, overseen by Judge M. Casey Rodgers. The number of cases has rapidly expanded, starting with dozens in early 2025 and projected to exceed tens of thousands as more plaintiffs come forward and awareness grows.

The MDL structure allows for streamlined pretrial proceedings, coordinated discovery, and the appointment of leadership committees for both plaintiffs and defense counsel. Plaintiffs are permitted to file directly into the MDL from any state, simplifying the filing process for eligible individuals nationwide. Aggressive discovery schedules are underway, with expert testimony and preemption arguments set to play key roles in shaping the outcomes of early bellwether trials.

In addition to the federal MDL, parallel state court cases are also moving forward in jurisdictions like California, Pennsylvania, Missouri, and Indiana. Some plaintiffs have filed state court cases strategically to leverage state consumer protection laws or more favorable jury pools. Bellwether trials in both federal and state courts are expected to begin in 2026, which will likely drive future settlement negotiations.

Contact Our Lawyers If You Believe You Qualify

If you or someone you love developed a meningioma after receiving Depo-Provera injections, you may qualify to pursue legal action and seek financial compensation. Our attorneys at Alonso Krangle, LLP are actively reviewing Depo-Provera lawsuits and can help you determine if you meet the eligibility criteria based on your medical history and drug usage.

Time is critical in these cases. The earlier you act, the better positioned you are to gather the necessary medical records, pharmacy documentation, and expert opinions required to support your claim. Contact Alonso Krangle, LLP today at 800-403-6191 or complete our secure online for a free case evaluation. We are committed to fighting for justice on behalf of those harmed by pharmaceutical companies that failed to put patient safety first.